| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2013 | WO2013064585A1 Treatment of musculoskeletal fibroproliferative disorders |
| 05/10/2013 | WO2013064584A1 Double-stranded RNA for immunostimulation |
| 05/10/2013 | WO2013064579A1 Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors |
| 05/10/2013 | WO2013064567A1 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases |
| 05/10/2013 | WO2013064538A1 Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection |
| 05/10/2013 | WO2013064535A1 Pharmaceutical composition of omeprazole |
| 05/10/2013 | WO2013064521A1 Pesticidal compounds |
| 05/10/2013 | WO2013064520A1 Pesticidal compounds |
| 05/10/2013 | WO2013064468A1 Indole inhibitors of crac |
| 05/10/2013 | WO2013064467A1 Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase |
| 05/10/2013 | WO2013064465A1 New aryl-quinoline derivatives |
| 05/10/2013 | WO2013064461A2 Compounds with nematicidal activity |
| 05/10/2013 | WO2013064451A1 Novel process for the preparation of acylguanidines and acylthioureas |
| 05/10/2013 | WO2013064450A1 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| 05/10/2013 | WO2013064445A1 Imidazopyridazine compounds |
| 05/10/2013 | WO2013064307A1 Ivabradine hydrochloride form iv |
| 05/10/2013 | WO2013064231A1 SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| 05/10/2013 | WO2013064193A1 Pharmaceutical compositions comprising sevelamer |
| 05/10/2013 | WO2013064161A1 Polyguanidine silicate and use thereof |
| 05/10/2013 | WO2013064128A1 Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
| 05/10/2013 | WO2013064083A1 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof |
| 05/10/2013 | WO2013064068A1 Thienopyrimidine and furopyrimidine derivatives, preparation method thereof and medical use thereof |
| 05/10/2013 | WO2013064031A1 N-benzylaniline derivative and uses thereof |
| 05/10/2013 | WO2013064029A1 Benzoylurea derivative with anticancer activity and preparation method and use thereof |
| 05/10/2013 | WO2013063889A1 Use of multiflora glycoside in preparing anti-hypoxic drug |
| 05/10/2013 | WO2013063695A1 Compositions and methods for preventing and treating oral diseases |
| 05/10/2013 | WO2013063679A1 Use of neul sialidase inhibitors in the treatment of cancer |
| 05/10/2013 | WO2013063673A1 Pharmaceutical composition and use thereof |
| 05/10/2013 | WO2013044356A9 Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
| 05/10/2013 | WO2013040552A3 Methods of promoting immune tolerance |
| 05/10/2013 | WO2013040471A3 Noribogaine salt ansolvates |
| 05/10/2013 | WO2013040439A3 CBP and p300-MEDIATED TRANSCRIPTION MODULATORS AND RELATED METHODS |
| 05/10/2013 | WO2013040436A3 Esx-mediated transcription modulators and related methods |
| 05/10/2013 | WO2013040286A3 Pharmaceutical compositions |
| 05/10/2013 | WO2013039428A3 Quinoline derivatives and method for producing and using same |
| 05/10/2013 | WO2013039350A3 Skin composition for external use containing ceramides |
| 05/10/2013 | WO2013032231A3 Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor |
| 05/10/2013 | WO2013032230A3 Pharmaceutical angiogenic composition including a microrna-382 activator |
| 05/10/2013 | WO2013032201A3 Material for preventing adhesion, and method for preventing adhesion |
| 05/10/2013 | WO2013026021A3 Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
| 05/10/2013 | WO2013025790A3 No- and h2s- releasing compounds |
| 05/10/2013 | WO2013023793A3 Matrices comprising a modified polysaccharide |
| 05/10/2013 | WO2013022783A3 Progesterone containing oral dosage forms and related methods |
| 05/10/2013 | WO2013022740A3 Gpr35 ligands and the uses thereof |
| 05/10/2013 | WO2013015979A3 Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
| 05/10/2013 | WO2013013238A3 Compounds and related compositions and methods of use |
| 05/10/2013 | WO2013010018A3 Compositions and methods for inhibiting proteases |
| 05/10/2013 | WO2013008164A3 Method of treating atherosclerosis in high triglyceride subjects |
| 05/10/2013 | WO2013006308A3 Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders |
| 05/10/2013 | WO2013005170A4 Inhibitors of aquaglyceroporins, methods and uses thereof |
| 05/10/2013 | WO2013003547A3 Bhq-conjugates, and related compounds, methods of making the same, and methods of use thereof |
| 05/10/2013 | WO2012178022A3 Therapeutic applications targeting sarm1 |
| 05/10/2013 | WO2012178015A3 Lrrk2 inhibitors |
| 05/10/2013 | WO2012177756A3 Non-leaching antimicrobial wound dressing |
| 05/10/2013 | WO2012177653A3 Targeting the neuromuscular junction for treatment |
| 05/10/2013 | WO2012170504A3 Treatment of extracellular matrix to reduce inflammation |
| 05/10/2013 | WO2012167133A3 Inhibitors of anandamide transport and their therapeutic uses |
| 05/10/2013 | WO2012158933A3 Macrocycllc therapeutic agents and methods of treatment |
| 05/10/2013 | WO2012158413A3 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| 05/10/2013 | WO2012156317A3 Intranasal pharmaceutical dosage forms comprising naloxone |
| 05/10/2013 | WO2012124311A8 Novel phenylpyridine derivative and drug containing same |
| 05/10/2013 | WO2012117334A8 Mglur5 positive allosteric modulators for use in the treatment of phelan-mcdermid syndrome |
| 05/10/2013 | WO2012112548A3 Firmocidin, an antimicrobial molecule produced by staphylococcus epidermidis |
| 05/10/2013 | WO2012019435A3 Composition for treating neurodegenerative disease or neuropathological condition |
| 05/10/2013 | WO2012006068A3 Compounds for the inhibition of cellular proliferation |
| 05/10/2013 | CA2858246A1 Use of neu1 sialidase inhibitors in the treatment of cancer |
| 05/10/2013 | CA2855641A1 Optically active fluconazole analogues containing thiophenes as antifungal agents |
| 05/10/2013 | CA2855019A1 Biaryl ether sulfonamides and their use as therapeutic agents |
| 05/10/2013 | CA2854612A1 Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts |
| 05/10/2013 | CA2854549A1 Ivabradine hydrochloride form iv |
| 05/10/2013 | CA2854471A1 Pak inhibitors for the treatment of cell proliferative disorders |
| 05/10/2013 | CA2854462A1 Pak inhibitors for the treatment of fragile x syndrome |
| 05/10/2013 | CA2854461A1 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/10/2013 | CA2854447A1 Method of treatment |
| 05/10/2013 | CA2854430A1 Liposomal corticosteroids for treatment of inflammatory disorders in humans |
| 05/10/2013 | CA2854398A1 Methods and compositions for modulating gastrointestinal bacteria to promote health |
| 05/10/2013 | CA2854361A1 Subcutaneous delivery of polymer conjugates of therapeutic agents |
| 05/10/2013 | CA2854349A1 Drugs for inhibiting p38 and uses thereof |
| 05/10/2013 | CA2854225A1 Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
| 05/10/2013 | CA2854221A1 Novel process for the preparation of acylguanidines and acylthioureas |
| 05/10/2013 | CA2854217A1 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| 05/10/2013 | CA2854215A1 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17.beta.-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis |
| 05/10/2013 | CA2854164A1 Dermal delivery compositions and methods |
| 05/10/2013 | CA2854163A1 Compositions and methods for inducing disruption of blood vasculature and for reducing angiogenesis |
| 05/10/2013 | CA2854160A1 Methods and compositions for wound treatment |
| 05/10/2013 | CA2854159A1 N- (3-{[(3-{[2-chloro-5-(methoxy)phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3- kinase inhibitor for the treatment of lymphoproliferative malignancies |
| 05/10/2013 | CA2854083A1 Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
| 05/10/2013 | CA2854066A1 Cationic lipid |
| 05/10/2013 | CA2853975A1 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853971A1 Improving recognition |
| 05/10/2013 | CA2853970A1 Alkylated piperazine compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853967A1 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
| 05/10/2013 | CA2853961A1 Compositions and methods for reduction of amyloid-beta load |
| 05/10/2013 | CA2853949A1 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/10/2013 | CA2853945A1 Methods and compositions for treatment of autism |
| 05/10/2013 | CA2853931A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | CA2853926A1 Method for improving executive function |
| 05/10/2013 | CA2853918A1 Gene therapy for diabetic neuropathy using an hgf isoform |
| 05/10/2013 | CA2853857A1 Compositions and methods for preventing and treating oral diseases |
| 05/10/2013 | CA2853806A1 Combination therapy of hsp90 inhibitors with platinum-containing agents |